JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

Search

uniQure NV

Avatud

70.1 0.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

67.75

Max

71.06

Põhinäitajad

By Trading Economics

Sissetulek

5.9M

-38M

Müük

3.7M

5.3M

Kasumimarginaal

-716.819

Töötajad

209

EBITDA

-4.5M

-44M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+11.16% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

3.1B

3.9B

Eelmine avamishind

69.9

Eelmine sulgemishind

70.1

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

uniQure NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 15:18 UTC

Suurimad hinnamuutused turgudel

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

24. sept 2025, 18:51 UTC

Tulu

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

uniQure NV Prognoos

Hinnasiht

By TipRanks

11.16% tõus

12 kuu keskmine prognoos

Keskmine 75.5 USD  11.16%

Kõrge 110 USD

Madal 56 USD

Põhineb 12 Wall Streeti analüütiku instrumendi uniQure NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

11

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

10.05 / 14.75Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
help-icon Live chat